Ocugen

Happy New Year from Ocugen. Wishing you joy and peace in 2025. #HappyNewYear #2025

Ocugen has been named in notable industry and investment lists for the Company’s progress across its modifier gene therapy programs. CGTLive included Dr. Shankar Musunuri’s interview on Continuing Research with Gene Therapy in Inherited Retina Diseases: https://bit.ly/3BPHypN and Dr. Arun Upadhyay’s interview on the Potential of Gene Therapy in Inherited Retinal Disease: https://bit.ly/4gNP2sa among its Most-Watched Expert Interviews of 2024: https://bit.ly/49YxqrA Ocugen was also named by Zacks Investment Research as one of the five most enthralling biotech breakthrough stocks to watch in 2025 for investors looking to diversify away from traditional pharmaceuticals: https://bit.ly/3VRIkJS We look forward to the continued advancement of the Phase 3 OCU400 liMeliGhT clinical trial for RP, Phase 1/2 OCU410 ArMaDa clinical trial for GA, and Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease in the year ahead! #GeneTherapy #BlindnessDiseases #RP #GA #ST

Ocugen has developed a novel modifier gene therapy that has the potential to be a one-time, gene-agnostic treatment for retinitis pigmentosa (RP). To hear from a participant in the Phase 1/2 OCU400 clinical trial, watch our patient video here: https://bit.ly/49X4jVC

We're #hiring a new Clinical Trial Manager in Malvern, Pennsylvania. Apply today or share this post with your network.

Ocugen wishes a Happy Hanukkah to all who celebrate. May these eight days be a joy for you and your family. #HappyHanukkah

Ocugen wishes you a Merry Christmas. We hope you spend the day with loved ones to celebrate the Christmas spirit. #MerryChristmas

The Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial convened and assessed data on 15 subjects from Phase 2. Initial data indicates that OCU410 appears to be safe and well-tolerated. Read the full press release for more details: https://bit.ly/3PaDi7b

Forbes London has named Dr. Huma Qamar as one of the Top Entrepreneurs of 2025, recognizing her excellence in clinical research, public health, and gene therapy. Thank you for sharing your visionary mindset with Ocugen and driving the Company’s clinical programs with positivity and passion. #Leadership #ClinicalTrials #CourageousInnovation

During the Ocugen holiday party, Dr. Syed M. Shah, Vitreoretinal Diseases and Surgery/Emplify Health, Vice Chair For Research & Digital Health, Gundersen Health – La Crosse, Wisconsin and PI for the Phase 1/2 OCU410 ArMaDa clinical trial, moderated a patient panel that included two Ocugen clinical trial participants--one with retinitis pigmentosa (RP) and one with Stargardt disease. It was a pleasure to hear from these patients and learn more about their experiences with modifier gene therapy treatment. Their presence put into perspective the hard work that every staff member puts in each day. #Patientcentric #CourageousInnovation #IRD #RP #Stargardt

Ocugen announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at the Oppenheimer Movers in Rare Disease Summit tomorrow in NYC. Read more https://bit.ly/3ZLeZ65